

INAMED CORP  
Form 425  
February 22, 2006

Filed By Allergan, Inc.  
Pursuant to Rule 425 under the  
Securities Act of 1933, as amended  
Subject Company: Inamed Corporation  
Registration No. 333-129871

**ALLERGAN EXTENDS EXPIRATION DATE OF INAMED EXCHANGE OFFER**

IRVINE, Calif., February 21, 2006 - - Allergan, Inc. (NYSE: AGN) today announced that it is extending the expiration date of its exchange offer for all outstanding shares of common stock of Inamed Corporation (NASDAQ: IMDC).

The exchange offer will now expire at 6:00 p.m. Eastern Time on March 8, 2006, and is being extended as U.S. antitrust approval of the Inamed acquisition has not yet been received. The exchange offer previously was scheduled to expire at 5:00 p.m. Eastern Time on Wednesday, February 22, 2006. As of 4:00 p.m. Eastern Time on Tuesday, February 21, 2006, approximately 18,727,874 shares, representing approximately 51%, of Inamed's outstanding common stock had been tendered.

Allergan also announced today that it has delivered to Inamed written notice to extend the deadline for closing the exchange offer from February 28, 2006, to March 30, 2006, as permitted under the terms of the merger agreement between Allergan and Inamed.

The U.S. antitrust approval is the only remaining antitrust clearance required to complete the Inamed acquisition. To facilitate U.S. antitrust approval of the acquisition, Allergan and Inamed continue to work with the Federal Trade Commission (FTC) to finalize Inamed's divestiture of its Reloxin® license.

We continue to make good progress in our proposed plan for the divestiture of Reloxin® and are hopeful that the FTC will conclude their review shortly, said David E.I. Pyott, Allergan's Chairman of the Board and Chief Executive Officer.

As previously stated, Allergan intends to promptly announce the results of the U.S. antitrust review upon completion, and will allow at least three business days after announcing the conclusion of the review before completing the exchange offer.

In the exchange offer, Allergan is offering to exchange for each outstanding share of common stock of Inamed Corporation, either \$84 in cash or 0.8498 of a share of Allergan common stock, at the election of the holder. Elections of Inamed stockholders are subject to proration as described in Allergan's Form S-4 registration statement initially filed with the Securities and Exchange Commission (SEC) on November 21, 2005, and subsequently amended, so that 45% of the aggregate Inamed shares tendered will be exchanged for cash and 55% of the aggregate Inamed shares tendered will be exchanged for shares of Allergan common stock.

To learn more about Allergan's exchange offer for Inamed and the details of the transaction, please go to the Allergan website [www.Allergan.com](http://www.Allergan.com).

**About Allergan, Inc.**

Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, medical aesthetics and other specialty markets

that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives.

**Forward-Looking Statements**

This press release contains forward-looking statements, including, among other statements, statements regarding the proposed business combination between Allergan and Inamed. Statements made in the future tense, and words such as expect, believe, will, may, anticipate and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations, but are subject to certain risks and uncertainties, many of which are difficult to predict and are beyond the control of Allergan. Relevant risks and uncertainties include those referenced in Allergan's filings with the SEC (which can be obtained as described in Additional Information below), and include: general industry and pharmaceutical market conditions; general domestic and international economic conditions; technological advances and patents obtained by competitors; challenges inherent in product marketing such as the unpredictability of market acceptance for new pharmaceutical and biologic products and/or the acceptance of new indications for such products; uncertainties regarding analysts' and others' projections and estimates for revenues and earnings of Inamed and market growth rates; domestic and foreign health care reforms; the timing and uncertainty of research and development and regulatory processes; trends toward managed care and health care cost containment; and governmental laws and regulations affecting domestic and foreign operations. Risks and uncertainties relating to the proposed Inamed acquisition include: that required regulatory approvals will not be obtained in a timely manner, if at all; that the anticipated benefits and synergies of the transaction will not be realized; that the integration of Inamed's operations with Allergan will be materially delayed or will be more costly or difficult than expected; and that the proposed transaction will not be consummated. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered.

**Additional Information**

Allergan has filed a Registration Statement on Form S-4 and a Tender Offer Statement on Schedule TO in connection with the exchange offer. Inamed stockholders should read those filings, and any other filings made by Allergan with the SEC in connection with the proposed Inamed acquisition, as they contain important information. These SEC filings, as well as Allergan's other public SEC filings, can be obtained without charge at the SEC's website at [www.sec.gov](http://www.sec.gov), and at Allergan's website at [www.Allergan.com](http://www.Allergan.com).

**Contact Information**

|  |                              |
|--|------------------------------|
| Amy Bilbija or Dan Burch, MacKenzie Partners | 212-929-5500 or 800-322-2885 |
| Allergan Investor Relations                  | 714-246-4636                 |
| Allergan Media Relations                     | 714-246-5134                 |
|  | ###                          |